Xynomic pharmaceuticals holdings, inc. (BCAC)
CashFlow / Yearly
Dec'18Dec'17
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income

266

-41

Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account

1,121

341

Unrealized loss on marketable securities held in Trust Account

-19

-17

Changes in operating assets and liabilities:
Prepaid expenses

-62

89

Accounts payable and accrued expenses

86

78

Net cash used in operating activities

-687

-376

CASH FLOWS FROM INVESTING ACTIVITIES:
Investment of cash and securities held in Trust Account

-

61,884

Net cash (used in)/provided by investing activities

-

-61,884

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of advances from related parties

-

157

Proceeds from issuance of convertible notes

400

-

Proceeds from issuance of ordinary shares

-

25

Proceeds from sale of Units, net of underwriting discounts paid

-

58,563

Proceeds from sale of Private Units

-

4,320

Proceeds from sale of unit purchase option

-

0

Proceeds from promissory note - related party

-

71

Proceeds from promissory note - related party

200

-

Repayment of promissory note - related party

-

300

Payment of offering costs

-

351

Net cash provided by/(used in) financing activities

600

62,172

NET INCREASE/(DECREASE) IN CASH

-87

-88

NON-CASH INVESTMENT AND FINANCING ACTIVITIES
Offering costs charged to additional paid in capital

-

402

Initial classification of ordinary shares subject to possible redemption

-

57,468

Change in value of ordinary shares subject to possible redemption

266

-40